Equities

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.99
  • Today's Change-0.14 / -6.57%
  • Shares traded16.25k
  • 1 Year change-52.68%
  • Beta--
Data delayed at least 15 minutes, as of Sep 29 2022 17:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-21.37m
  • Incorporated2006
  • Employees37.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.